{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"12.8","value":"1.9"},{"groupId":"OG001","lowerLimit":"0.8","upperLimit":"4.8","value":"1.0"},{"groupId":"OG002","lowerLimit":"1.0","upperLimit":"9.0","value":"1.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"description":"TTR is defined as the time from the start of treatment to the first documented response (Partial Response, Very Good Partial Response or Complete Response) based on according to modified International Myeloma Working Group (mIMWG) criteria.\n\nCR=Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow VGPR=Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \\< 100 mg per 24 hours PR=≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \\< 200 mg per 24 hours. Based on Kaplan-Meier Estimates","dispersionType":"Full Range","groups":[{"description":"(Pomalidomide + low dose Dexamethasone) in participants with 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old).","id":"OG000","title":"Cohort A"},{"description":"(Pomalidomide + Daratumumab + low dose Dexamethasone) in participants with 1 or 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old). DARA was administered intravenously (IV) at a starting dose of 16 mg/kg.","id":"OG001","title":"Cohort B"},{"description":"(Pomalidomide + Daratumumab + low dose Dexamethasone) in Japanese participants with 1 or 2 prior lines of therapy with the most recent line of therapy containing lenalidomide. The starting dose level of POM was 4 mg. The starting dose level of Dex was 40 mg/day (≤75 years old) or 20 mg/day (\\> 75 years old). DARA was administered intravenously (IV) at a starting dose of 16 mg/kg.","id":"OG002","title":"Cohort C"}],"paramType":"MEDIAN","populationDescription":"All responders (PR, VGPR, CR)","reportingStatus":"POSTED","timeFrame":"From first dose until the first documented response (Up to 130 months)","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"Months"}